Meta-Analysis of the Prevalence of Arterial Hypertension in Kazakhstan

Yerke Suleimenova; Yerzhan  Kuanyshbekov; Arslan  Abdullayev; Nurzhamal  Akhmadyar; Indira  Karibayeva

doi:10.23750/abm.v96i6.17171

Authors

Yerke Suleimenova Department of Clinical Pharmacology, Astana Medical University, Astana, Kazakhstan https://orcid.org/0009-0002-5543-8635
Yerzhan Kuanyshbekov Department of Spinal Neurosurgery and Peripheral Nervous System Pathology, National center for Neurosurgery, Astana, Kazakhstan https://orcid.org/0009-0007-5142-833X
Arslan Abdullayev Department of Surgery “City Polyclinic No. 9” of the Akimat of Astana City, Astana, Kazakhstan https://orcid.org/0009-0001-1061-2145
Nurzhamal Akhmadyar Department of Clinical Pharmacology, Astana Medical University, Astana, Kazakhstan https://orcid.org/0000-0002-8829-1281
Indira Karibayeva Department of Health Policy and Community Health, Jiann-Ping Hsu College of Public Health, Georgia Southern University, Statesboro, GA 30460, USA https://orcid.org/0000-0003-1796-2604

Keywords:

Arterial hypertension, prevalence, systematic review, meta-analysis, Kazakhstan.

Abstract

Background and aim: Arterial hypertension is a major global health concern and a leading risk factor for cardiovascular diseases, stroke, and kidney failure. The prevalence of hypertension continues to rise due to sedentary lifestyles, urbanization, and aging populations. In Kazakhstan, hypertension represents a growing burden, with an estimated 3.8 million affected adults and low control rates. This systematic review and meta-analysis assessed the prevalence of arterial hypertension in Kazakhstan by synthesizing data from observational studies.

Methods: A systematic literature search was conducted across PubMed, Scopus, ScienceDirect, Web of Science, and Google Scholar. Studies were selected based on predefined inclusion and exclusion criteria. Data extraction followed PRISMA guidelines. The Newcastle–Ottawa Scale (NOS) was used to evaluate the quality. Meta-analysis was performed to calculate the pooled estimates with heterogeneity assessed through evaluation and meta regression.

Results: Out of 335 titles assessed a total of five studies met the inclusion criteria, involving 4,716 participants from multiple regions of Kazakhstan. The pooled prevalence of arterial hypertension was 27% (95% CI: 20–34%), with significant heterogeneity (I² = 99%). Meta-regression suggested that sample size was not a significant predictor of prevalence variability. Studies varied in terms of study design, population characteristics, and diagnostic criteria.

Conclusions: This review revealed high prevalence of hypertension in Kazakhstan. Targeted public health interventions, enhanced primary care, and improved data collection are essential to reduce disease burden. Emphasizing health education, regional policy planning, and digital health tools will support better hypertension control across the country.

Author Biography

Yerke Suleimenova, Department of Clinical Pharmacology, Astana Medical University, Astana, Kazakhstan

MD, MS in Pharmacology and Toxicology, MS in Clinical Research Candidate

References

1. Farrington J, Kontsevaya A, Dombrovskiy V, et al. Prevention and control of noncommunicable diseases in Kazakhstan: the case for investment. Copenhagen: WHO Regional Office for Europe; 2019. doi: https://iris.who.int/handle/10665/346422.

2. Glushkova N, Turdaliyeva B, Kulzhanov M, et al. Examining disparities in cardiovascular disease prevention strategies and incidence rates between urban and rural populations: insights from Kazakhstan. Sci Rep. 2023;13:20917. doi: 10.1038/s41598-023-47899-8.

3. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16:223вЂ“237. doi: 10.1038/s41581-019-0244-2.

4. Mukhtarkhanova DM, Junusbekova GA, Tundybayeva MK, et al. Arterial hypertension and associated risk factors in Kazakhstan: an analysis of blood pressure screening results from May Measurement Month 2021вЂ“2023. High Blood Press Cardiovasc Prev. 2025. Ahead of print. doi: 10.1007/s40119-025-00412-w.

5. Miall WE, Oldham PD. The hereditary factor in arterial blood-pressure. Br Med J. 1963;1:75вЂ“80. doi: 10.1136/bmj.1.5323.75.

6. Yerdessov S, Kadyrzhanuly K, Sakko Y, et al. Epidemiology of arterial hypertension in Kazakhstan: data from Unified Nationwide Electronic Healthcare System 2014вЂ“2019. J Cardiovasc Dev Dis. 2022;9:52. doi: 10.3390/jcdd9020052.

7. Moiynbayeva S, Akhmetov V, Narymbayeva N, et al. Health policy implications for cardiovascular disease, type 2 diabetes mellitus, and stroke in Central Asia: a decadal forecast of their impact on women of reproductive age. Front Public Health. 2024;12:1456187. doi: 10.3389/fpubh.2024.1456187.

8. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71.

9. Nugmanova A, Pillai G, Nugmanova D, Kuter D. Improving the management of hypertension in Kazakhstan: implications for improving clinical practice, patient behaviours and health outcomes. Chronic Illn. 2008;4:214вЂ“231. doi: 10.1080/17441690701872664.

10. Footman K, Roberts B, Tumanov S, McKee M. The comorbidity of hypertension and psychological distress: a study of nine countries in the former Soviet Union. J Public Health (Oxf). 2013;35:548вЂ“557. doi: 10.1093/pubmed/fdt019.

11. Supiyev A, Kossumov A, Utepova L, et al. Prevalence, awareness, treatment and control of arterial hypertension in Astana, Kazakhstan: a cross-sectional study. Public Health. 2015;129:948вЂ“953. doi: 10.1016/j.puhe.2015.02.020.

12. Markabayeva A, Bauer S, Pivina L, et al. Increased prevalence of essential hypertension in areas previously exposed to fallout due to nuclear weapons testing at the Semipalatinsk Test Site, Kazakhstan. Environ Res. 2018;166:629вЂ“635. doi: 10.1016/j.envres.2018.07.016.

13. Makhambetchin Y, Yessembekova A, Nurbakyttana A, et al. Trends in the dynamics of morbidity and mortality from hypertension in the Republic of Kazakhstan from 2010 to 2019. Pol Merkur Lekarski. 2024;52:95вЂ“103. doi: 10.36740/merkur202401115.

14. Harrer M, Cuijpers P, Furukawa T, Ebert D. Doing meta-analysis with R: a hands-on guide. New York: Chapman and Hall/CRC; 2021. doi: 10.1201/9781003107347.

15. Mukhtarkhanova D, Junusbekova G, Tundybayeva M, et al. Assessment of the prevalence of arterial hypertension in young non-organised population of the Republic of Kazakhstan. J Hypertens. 2024;42(Suppl 1):e162. doi: 10.1097/01.hjh.0001020996.32576.0b.

16. Khamidullaeva G, Ataniyazov K, Fozilov K, Abdullaeva S. Prevalence of risk factors and target organ damage caused by hypertension in residents of the Aral sea region of Uzbekistan. J Hypertens. 2024;42(Suppl 1):e276. doi: 10.1097/01.hjh.0001022352.42836.9a.

17. Polupanov AG, Khalmatov AN, Altymysheva AT, et al. The prevalence of major cardiovascular risk factors in a rural population of the Chui region of Kyrgyzstan: the results of an epidemiological study. Anatol J Cardiol. 2020;24:183вЂ“191.

18. Wang J, Zhang L, Wang F, Liu L, Wang H. Prevalence, awareness, treatment, and control of hypertension in China: results from a national survey. Am J Hypertens. 2014;27:1355вЂ“1361. doi: 10.1093/ajh/hpu053.

19. Anchala R, Kannuri NK, Pant H, et al. Hypertension in India: a systematic review and meta-analysis of prevalence, awareness, and control of hypertension. J Hypertens. 2014;32:1170вЂ“1177. doi: 10.1097/HJH.0000000000000146.

20. Cheung BM, Ong KL, Man YB, Lam KSL, Lau CP. Prevalence, awareness, treatment, and control of hypertension: United States National Health and Nutrition Examination Survey 2001вЂ“2002. J Clin Hypertens (Greenwich). 2007;9:120вЂ“126. doi: 10.1111/j.1524-6175.2006.04895.x.